1. Home
  2. ACAD vs NP Comparison

ACAD vs NP Comparison

Compare ACAD & NP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.58

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Neptune Insurance Holdings Inc.

NP

Neptune Insurance Holdings Inc.

HOLD

Current Price

$31.73

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
NP
Founded
1993
2017
Country
United States
United States
Employees
N/A
60
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.4B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ACAD
NP
Price
$25.58
$31.73
Analyst Decision
Buy
Buy
Analyst Count
22
12
Target Price
$30.55
$28.17
AVG Volume (30 Days)
1.9M
987.4K
Earning Date
05-06-2026
04-22-2026
Dividend Yield
N/A
N/A
EPS Growth
69.12
N/A
EPS
0.02
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
$25.84
Revenue Next Year
$11.70
$15.80
P/E Ratio
$1,311.00
N/A
Revenue Growth
40.45
N/A
52 Week Low
$19.69
$14.78
52 Week High
$28.35
$34.61

Technical Indicators

Market Signals
Indicator
ACAD
NP
Relative Strength Index (RSI) 64.96 57.63
Support Level $25.40 $23.62
Resistance Level $27.79 N/A
Average True Range (ATR) 0.92 1.71
MACD 0.13 0.04
Stochastic Oscillator 67.55 61.75

Price Performance

Historical Comparison
ACAD
NP

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About NP Neptune Insurance Holdings Inc.

Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.

Share on Social Networks: